Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Schizophrenia, Cognition, Psychosis

In brief

The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.

Key facts

Study ID

NCT02104752

Run by

VA Greater Los Angeles Healthcare System

People needed

39

Starts

2014-07-01

Expected to finish

2017-10-01

Last updated by the study team

2019-05-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-5 diagnosis of schizophrenia
• age 18 - 65 years
• understand spoken English sufficiently to comprehend testing procedures
• corrected vision of at least 20/30
• currently prescribed an antipsychotic medication

You may not qualify if…

• clinically significant neurological disease determined by medical history (e.g., epilepsy)
• history of serious head injury (i.e., loss of consciousness > 1 hr., no neuropsychological sequelae, no cognitive rehabilitation post head injury)
• sedatives or benzodiazepines within 12 hrs of testing
• any psychiatric hospitalization within 3 months prior to study participation
• behaviors suggesting any potential danger to self or others within 6 months prior to study participation
• antipsychotic dose change more than 50% over the 3 months prior to study participation
• acute medical problems or untreated chronic medical conditions within 3 months prior to study participation

Where it is running

• VA Greater Los Angeles — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.